Clinical Trial Radar

Cancers considered to be from an oral cavity site (oral tongue, floor of mouth, alveolar ridge, buccal or lip), or the nasopharynx, hypopharynx, or larynx, even if p16 positive;

Carcinoma of the neck of unknown primary site origin (even if p16 positive)

Distant metastasis or adenopathy below the clavicles;

Gross total excision of both primary and nodal disease; this includes tonsillectomy, local excision of primary site, and nodal excision that removes all clinically and radiographically evident disease.

Simultaneous primary cancers or separate bilateral primary tumor sites;

Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 years) (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible);

Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable;

Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields;

Severe, active co-morbidity defined as follows:

1. Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months;
2. Transmural myocardial infarction within the last 6 months;
3. Acute bacterial or fungal infection intravenous antibiotics at the time of registration;
4. Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration;
5. Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol other than those listed in 5.1.
6. Acquired immune deficiency syndrome (AIDS) based upon the current CDC definition with immune compromise greater than that noted in section 5.1; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. Protocol-specific requirements may also exclude immune-compromised patients.

Pregnancy; this exclusion is necessary because the treatment in this study may be significantly teratogenic

Prior allergic reaction to cisplatin.

Exclusion Criteria for MRI: Normal MRI exclusion criteria will apply, including those on the following list. A standard MRI safety form will be used to identify potential conditions warranting exclusion.

Electrical implants such as cardiac pacemakers or perfusion pumps

Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial heart, valves with steel parts, metal fragments, shrapnel, bullets, tattoos near the eye, or steel implants

Ferromagnetic objects such as jewelry or metal clips in clothing

Claustrophobia

History of seizures

Patients with GFR < 15 ml/min/1.73m2 or who are on dialysis will not have DCE-MRI scan. These patients will have conventional anatomical MRI without contrast and DW-MRI.